Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.

Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM.

J Clin Psychopharmacol. 2008 Apr;28(2):156-65. doi: 10.1097/JCP.0b013e31816774f9.

PMID:
18344725
2.

Venlafaxine extended-release: a review of its use in the management of major depression.

Wellington K, Perry CM.

CNS Drugs. 2001;15(8):643-69. Review.

PMID:
11524036
3.

Aripiprazole: in major depressive disorder.

Weber J, Lyseng-Williamson KA, Scott LJ.

CNS Drugs. 2008;22(10):807-13. Review.

PMID:
18788833
4.

Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.

Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ.

Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. Review.

PMID:
19919295
5.

Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed.

Citrome L, Ketter TA, Cucchiaro J, Loebel A.

J Affect Disord. 2014 Feb;155:20-7. doi: 10.1016/j.jad.2013.10.040. Review.

PMID:
24246116
8.

Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data.

Pae CU, Forbes A, Patkar AA.

CNS Drugs. 2011 Feb;25(2):109-27. doi: 10.2165/11538980-000000000-00000. Review.

PMID:
21254788
9.

Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder.

Blier P, Blondeau C.

J Affect Disord. 2011 Jan;128 Suppl 1:S3-10. doi: 10.1016/S0165-0327(11)70003-9. Review.

PMID:
21220079
11.

Second-generation antipsychotics in major depressive disorder: update and clinical perspective.

Chen J, Gao K, Kemp DE.

Curr Opin Psychiatry. 2011 Jan;24(1):10-7. doi: 10.1097/YCO.0b013e3283413505. Review.

PMID:
21088586
13.

[Efficacy of aripiprazole for the treatment of schizophrenia: what dose is required?].

Charpeaud T, Samalin L, Llorca PM.

Encephale. 2014 Feb;40(1):62-73. doi: 10.1016/j.encep.2013.12.002. Review. French.

PMID:
24445245
14.

Current evidence for aripiprazole as augmentation therapy in major depressive disorder.

Khan A.

Expert Rev Neurother. 2008 Oct;8(10):1435-47. doi: 10.1586/14737175.8.10.1435. Review.

PMID:
18928339
15.

Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients.

Dolder C, Nelson M, Stump A.

Drugs Aging. 2010 Aug 1;27(8):625-40. doi: 10.2165/11537140-000000000-00000. Review.

PMID:
20658791
16.

Quetiapine extended release: adjunctive treatment in major depressive disorder.

Sanford M.

CNS Drugs. 2011 Sep 1;25(9):803-13. doi: 10.2165/11207280-000000000-00000. Review.

PMID:
21870891
17.

Adjunctive Brexpiprazole: A Review in Major Depressive Disorder.

McKeage K.

CNS Drugs. 2016 Feb;30(2):91-9. doi: 10.1007/s40263-016-0320-0. Review.

PMID:
26849053
18.

Aripiprazole: in the treatment of irritability associated with autistic disorder in pediatric patients.

Curran MP.

Paediatr Drugs. 2011 Jun 1;13(3):197-204. doi: 10.2165/11207230-000000000-00000. Review.

PMID:
21500873
19.
20.

Discontinuation symptoms in depression and anxiety disorders.

Baldwin DS, Montgomery SA, Nil R, Lader M.

Int J Neuropsychopharmacol. 2007 Feb;10(1):73-84. Review.

PMID:
16359583
Items per page

Supplemental Content

Support Center